Relief of exhaustion in tumor infiltrating lymphocytes is currently under intensive study as a therapeutic method due to significant advancements in the care of patients with melanoma, non-small cell lung cancer, and others using PD-1 and CTLA-4 checkpoint blockade (13). This evidence concerns the gene CTLA4 and neoplasm.